Page 208 - Drug Class Review
P. 208
To investigate the efficacy and tolerability of GAL using slow dose escalating schedule of up to 8 weeks
Page 134 of 205
Drug Effectiveness Review Project
Authors and Years: Tairot et al., 2000; 52 Cummings et al., 2004; 64 Galasko et al., 2004 65
placebo N/A 5 months 286 History of cognitive decline gradual in onset and progressive over a period of at least 6 months; diagnosis of probable AD according to NINCDS/ADRDA; MMSE score 10 – 22; ADAS-Cog 11 score of >18 Any other neurodegenerative disorders; cardiovascular disease; clinically significant psychiatric, hepatic, renal pulmonary, metabolic, or endocrine conditions, or urinary outflow obstruction; active peptide ulcer; history of epilepsy or significant drug or alcohol abuse; treated for AD with a cholinomemetic agent in Concomitant medica
Drugs Janssen Research Foundation in 978 patients with mild to moderate AD Setting: Multi-center galantamine 8; 16; 24 mg/d 5 months 140; 279; 273
Alzheimer Country: US Study design: RCT Sample size: 978 preceding 60 days
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
